The FDA has signed off on the first in-human study of Abiomed’s (NASDAQ:ABMD) 9 French Impella ECP heart pump in high-risk percutaneous coronary intervention (PCI) patients.
The company says the device, designed for short-term mechanical circulatory support, is the world’s smallest heart pump.
https://seekingalpha.com/news/3580717-abiomed-on-go-study-of-new-heart-pump
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.